Episode Player
ALTERITY THERAPEUTICS LTD (ATH) - ATH434 And The Race To Treat MSA
ASX BRIEFS
MSA is rare, relentless, and too often diagnosed only after the most obvious neurological symptoms arrive. We’re joined by David Stamler, Managing Director and CEO of Alterity Therapeutics, to explain what multiple system atrophy can look like from the first vague signs through to rapid loss of mobility, and why symptomatic treatments leave such a large unmet need.
We talk through the phase two signal for ATH434, including what “48% slowing” on the MSA rating scale could translate to in everyday life, from walking and balance to tasks like dressing and eating, plus the importance of swallowing outcomes and orthostatic hypotension symptoms. David also shares how ATH434 is designed to work as an iron chaperone, why iron biology matters in neurodegenerative disease, and how new endpoints like digital biomarkers can track real-world walking with wearable sensors.
A major focus is the regulatory path: Alterity’s alignment with the US FDA at the end of phase two meeting, why it de-risks the program, and what the agreed phase three clinical trial design looks like. We cover the practical steps still required before first patient enrolment, the expected timeline to results, what larger partners look for in a program like this, and how manufacturing and patent strategy support longer-term value.
If you care about biotech, clinical trials, and the hunt for disease-modifying treatments in neurodegeneration, listen now and share this with someone following MSA research. Subscribe, leave a review, and tell us what question you want answered next.
